Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: A renal proximal tubule perspective

American Journal of Physiology - Cell Physiology

Volumn 318, Issue 2, 2020, Pages C328-C336

  Silva dos Santos, Danúbia ^a   Polidoro, Juliano Z ^a   Borges Júnior, Flávio A ^a   Girardi, Adriana C C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Extracellular volume; Heart failure; Hyperglycemia; Intrarenal angiotensin system; Na+ H+ exchanger isoform 3; Sympathetic nervous system

Indexed keywords

ALBUMIN; EMPAGLIFLOZIN; ERYTHROPOIETIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN 3; URIC ACID; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE; SLC5A2 PROTEIN, HUMAN; SODIUM;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART PROTECTION; HOMEOSTASIS; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERURICEMIA; KIDNEY PROXIMAL TUBULE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RISK REDUCTION; ADRENERGIC SYSTEM; CARDIOVASCULAR SYSTEM; DRUG EFFECT; KIDNEY; METABOLISM; PHARMACOLOGY;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY TUBULES, PROXIMAL; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 85078867251     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00275.2019     Document Type: Review

References (89)

1. Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci 20: 629, 2019. doi:10.3390/ijms20030629.
2. Barajas L, Powers K, Wang P. Innervation of the renal cortical tubules: a quantitative study. Am J Physiol 247: F50–F60, 1984. doi:10.1152/ ajprenal.1984.247.1.F50.
3. +-glucose cotransporter in hypertension. Am J Physiol Renal Physiol 286: F127–F133, 2004. doi:10.1152/ajprenal.00113.2003.
4. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21: 512–517, 2015. doi:10.1038/nm.3828.
5. + exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297: F1647–F1655, 2009. doi:10.1152/ajprenal.00082.2009.
6. Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M, Burns KD. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86: 1057–1058, 2014. doi:10.1038/ ki.2014.246.
7. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35: 391–404, 2014. doi:10.1002/bdd.1909.
8. Coady MJ, El Tarazi A, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY. MAP17 is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol 28 85–93, 2017. doi:10.1681/ASN.2015111282.
9. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BPM, Lessa LMA, Malnic G, Girardi ACC. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301: F355–F363, 2011. doi:10.1152/ajprenal.00729.2010.
10. Dhande I, Ali Q, Hussain T. Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension 61: 1218 –1226, 2013. doi:10.1161/ HYPERTENSIONAHA.111.00422.
11. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 11: 197–200, 2002. doi:10.1097/00041552-200203000-00011.
12. Farah LX, Valentini V, Pessoa TD, Malnic G, McDonough AA, Girardi AC. The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am J Physiol Renal Physiol 310: F123–F127, 2016. doi:10.1152/ajprenal.00394.2015.
13. + exchanger NHE3 by insulin. Am J Physiol Renal Physiol 292: F577–F585, 2007. doi:10.1152/ajprenal. 00240.2006.
14. Ghezzi C, Yu AS, Hirayama BA, Kepe V, Liu J, Scafoglio C, Powell DR, Huang SC, Satyamurthy N, Barrio JR, Wright EM. Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule. J Am Soc Nephrol 28: 802–810, 2017. doi:10.1681/ASN.2016050510.
15. + exchanger-3 regulation in organ dysfunction. Am J Physiol Cell Physiol 302: C1569–C1587, 2012. doi:10.1152/ajpcell.00017.2012.
16. + exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol 287: C1238–C1245, 2004. doi:10.1152/ajpcell.00186.2004.
17. Gurley SB, Riquier-Brison ADM, Schnermann J, Sparks MA, Allen AM, Haase VH, Snouwaert JN, Le TH, McDonough AA, Koller BH, Coffman TM. AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab 13: 469–475, 2011. doi:10.1016/j. cmet.2011.03.001.
18. Hallow KM, Greasley PJ, Helmlinger G, Chu L, Heerspink HJ, Boulton DW. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol 315: F1295–F1306, 2018. doi:10.1152/ajprenal. 00202.2018.
19. Harris RC, Brenner BM, Seifter JL. Sodium-hydrogen exchange and glucose transport in renal microvillus membrane vesicles from rats with diabetes mellitus. J Clin Invest 77: 724–733, 1986. doi:10.1172/JCI112367.
20. Hatanaka T, Ogawa D, Tachibana H, Eguchi J, Inoue T, Yamada H, Takei K, Makino H, Wada J. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 4: e00239, 2016. doi:10.1002/ prp2.239.
21. + exchanger 3 in the rat. Acta Physiol (Oxf) 210: 678–689, 2014. doi:10.1111/apha.12181.
22. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94: 26 –39, 2018. doi:10.1016/j.kint.2017.12.027.
23. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108: 3097–3101, 2003. doi:10.1161/01.CIR. 0000103123.66264.FE.
24. Inoue BH, dos Santos L, Pessoa TD, Antonio EL, Pacheco BPM, Savignano FA, Carraro-Lacroix LR, Tucci PJF, Malnic G, Girardi ACC. Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am J Physiol Regul Integr Comp Physiol 302: R166 –R174, 2012. doi:10.1152/ajpregu.00127.2011.
25. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41: 356 –363, 2018. doi:10.2337/dc17-1096.
26. Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K, Utsunomiya K. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci 18: 1083, 2017. doi:10.3390/ijms18051083.
27. Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140: 303–315, 2019. doi:10.1161/CIRCULATIONAHA.118.037418.
28. Klisic J, Nief V, Reyes L, Ambuhl PM. Acute and chronic regulation of the renal Na/H+ exchanger NHE3 in rats with STZ-induced diabetes mellitus. Nephron, Physiol 102: 27–35, 2006. doi:10.1159/000089091.
29. Kopp UC. Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol 308: R79–R95, 2015. doi:10.1152/ajpregu.00351.2014.
30. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853–862, 2013. doi:10.1111/ dom.12127.
31. + exchanger but not in mice lacking NHE2. Am J Physiol Renal Physiol 281: F718–F727, 2001. doi:10.1152/ajprenal.2001.281.4.F718.
32. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73: 913–919, 1986. doi:10.1161/01.CIR.73.5.913.
33. + exchanger 3) promotes the pressure-natriuresis response and lowers blood pressure in mice. Hypertension 72: 1328–1336, 2018. doi:10.1161/HYPERTENSIONAHA.118.10884.
34. Lin R, Murtazina R, Cha B, Chakraborty M, Sarker R, Chen TE, Lin Z, Hogema BM, de Jonge HR, Seidler U, Turner JR, Li X, Kovbasnjuk O, Donowitz M. D-Glucose acts via sodium/glucose cotransporter 1 to increase NHE3 in mouse jejunal brush border by a Na+/H+ exchange regulatory factor 2-dependent process. Gastroenterology 140: 560–571, 2011. doi:10.1053/j.gastro.2010.10.042.
35. Lütken SC, Kim SW, Jonassen T, Marples D, Knepper MA, Kwon TH, Frøkiaer J, Nielsen S. Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. Am J Physiol Renal Physiol 297: F1678 –F1688, 2009. doi:10.1152/ajprenal.00010.2009.
36. Lytvyn Y, Perkins BA, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 39: 239 –246, 2015. doi:10. 1016/j.jcjd.2014.10.013.
37. Maldonado-Cervantes MI, Galicia OG, Moreno-Jaime B, Zapata-Morales JR, Montoya-Contreras A, Bautista-Perez R, Martinez-Morales F. Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-α in LLC-PK(1) cells. J Physiol Biochem 68: 411–420, 2012. doi:10.1007/s13105-012-0153-3.
38. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 53: 875–883, 2009. doi:10.1053/j.ajkd.2008.12.031.
39. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl 79: S1–S6, 2011. doi:10.1038/ki.2010.509.
40. Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 35: 2059–2068, 2017. doi:10.1097/ HJH.0000000000001434.
41. Moe OW, Alpern RJ, Henrich WL. The renal proximal tubule renin-angiotensin system. Semin Nephrol 13: 552–557, 1993.
42. Nakamura N, Matsui T, Ishibashi Y, Yamagishi S. Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetol Metab Syndr 7: 48, 2015. doi:10.1186/s13098-015-0044-1.
43. Nascimento-Gomes G, Mello-Aires M. Effect of glucose on the kinetics of bicarbonate reabsorption in the early and middle proximal tubule. Braz J Med Biol Res 23: 79–85, 1990.
44. Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol 11: 180–186, 2011. doi:10.1016/j.coph.2011.01.009.
45. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017. doi:10.1056/NEJMoa1611925.
46. Osorio H, Bautista R, Rios A, Franco M, Santamaría J, Escalante B. Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 86: e46 –e49, 2009. doi:10.1016/j.diabres.2009.09.006.
47. Pacheco BPM, Crajoinas RO, Couto GK, Davel APC, Lessa LM, Rossoni LV, Girardi ACC. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 29: 520–528, 2011. doi:10.1097/HJH.0b013e328341939d.
48. Packer M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136: 1548–1559, 2017. doi:10.1161/CIRCULATIONAHA.117.030418.
49. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 8: e54442, 2013. doi:10.1371/journal.pone.0054442.
50. Peruchetti DB, Silva-Aguiar RP, Siqueira GM, Dias WB, Caruso-Neves C. High glucose reduces megalin-mediated albumin endocytosis in renal proximal tubule cells through protein kinase B O-GlcNAcylation. J Biol Chem 293: 11388–11400, 2018. doi:10.1074/jbc.RA117.001337.
51. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25: 2028–2039, 2014. doi:10.1681/ASN.2013060588.
52. Piperidou A, Sarafidis P, Boutou A, Thomopoulos C, Loutradis C, Alexandrou ME, Tsapas A, Karagiannis A. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37: 1334 –1343, 2019. doi:10.1097/HJH.0000000000002050.
53. + exchanger isoform 3 via angiotensin II type I receptor. Am J Physiol Renal Physiol 308: F848 –F856, 2015. doi:10.1152/ ajprenal.00515.2014.
54. Pribanic S, Gisler SM, Bacic D, Madjdpour C, Hernando N, Sorribas V, Gantenbein A, Biber J, Murer H. Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells. Am J Physiol Renal Physiol 285: F784–F791, 2003. doi:10.1152/ajprenal. 00109.2003.
55. Rafiq K, Fujisawa Y, Sherajee SJ, Rahman A, Sufiun A, Kobori H, Koepsell H, Mogi M, Horiuchi M, Nishiyama A. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58: 2885–2898, 2015. doi:10.1007/ s00125-015-3771-9.
56. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427–3434, 2005. doi:10.2337/diabetes.54.12.3427.
57. Ramkumar N, Kohan DE. Proximal tubule angiotensinogen modulation of arterial pressure. Curr Opin Nephrol Hypertens 22: 32–36, 2013. doi:10.1097/MNH.0b013e328359dbed.
58. Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag 12: 393–405, 2016. doi:10.2147/ VHRM.S111991.
59. Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, Sánchez D, Escalante B. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol 20: 292, 2019. doi:10.1186/s12882-019-1490-z.
60. Saad S, Stevens VA, Wassef L, Poronnik P, Kelly DJ, Gilbert RE, Pollock CA. High glucose transactivates the EGF receptor and upregulates serum glucocorticoid kinase in the proximal tubule. Kidney Int 68: 985–997, 2005. doi:10.1111/j.1523-1755.2005.00492.x.
61. Sano M, Chen S, Imazeki H, Ochiai H, Seino Y. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig 9: 638 –641, 2018. doi:10.1111/jdi.12726.
62. Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139: 1985–1987, 2019. doi:10.1161/ CIRCULATIONAHA.118.038881.
63. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol 73: 1931–1944, 2019. doi:10.1016/j. jacc.2019.01.056.
64. Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gawenis LR, Riddle TM, Duffy JJ, Doetschman T, Wang T, Giebisch G, Aronson PS, Lorenz JN, Shull GE. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet 19: 282–285, 1998. doi:10.1038/969.
65. Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin SE, Talsness CE, Dzau VJ. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90: 1523–1529, 1992. doi:10.1172/JCI116020.
66. Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One 11: e0165703, 2016. doi:10.1371/ journal.pone.0165703.
67. Staahltoft D, Nielsen S, Janjua NR, Christensen S, Skøtt O, Marcus-sen N, Jonassen TE. Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. Am J Physiol Renal Physiol 282: F307–F315, 2002. doi:10.1152/ajprenal.00132.2001.
68. Thomson R, Thomson B, Girardi A, Kocher O, Aronson P. Interaction of NHE3 with the proximal tubule brush border scaffolding protein PDZKI (Abstract). FASEB J 18: A320, 2004.
69. Thomson RB, Wang T, Thomson BR, Tarrats L, Girardi A, Mentone S, Soleimani M, Kocher O, Aronson PS. Role of PDZK1 in membrane expression of renal brush border ion exchangers. Proc Natl Acad Sci USA 102: 13331–13336, 2005. doi:10.1073/pnas.0506578102.
70. Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, Joles JA. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28: 1023–1039, 2017. doi:10.1681/ASN.2016060666.
71. Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, Tokuyama H, Wakino S, Itoh H. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep 8: 6791, 2018. doi:10.1038/s41598-018-25054-y.
72. + and vasodilation. Diabetologia 61: 722–726, 2018. doi:10.1007/s00125-017-4509-7.
73. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66: 255–270, 2015. doi:10.1146/ annurev-med-051013-110046.
74. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300: R1009–R1022, 2011. doi:10.1152/ajpregu.00809.2010.
75. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104 –112, 2011. doi:10.1681/ASN. 2010030246.
76. van de Borne P. The kidney and the sympathetic system: a short review. Curr Clin Pharmacol 8: 175–181, 2013. doi:10.2174/15748847113089990049.
77. Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2: 939 –940, 2017. doi:10.1001/ jamacardio.2017.1891.
78. Wang J, Shibayama Y, Kobori H, Liu Y, Kobara H, Masaki T, Wang Z, Nishiyama A. High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5. PLoS One 12: e0185600, 2017. doi:10.1371/journal.pone.0185600.
79. Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D’Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, Levi M. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292: 5335–5348, 2017. doi: 10.1074/jbc.M117.779520.
80. Winterberg PD, Wang Y, Lin KM, Hartono JR, Nagami GT, Zhou XJ, Shelton JM, Richardson JA, Lu CY. Reactive oxygen species and IRF1 stimulate IFNα production by proximal tubules during ischemic AKI. Am J Physiol Renal Physiol 305: F164–F172, 2013. doi:10.1152/ ajprenal.00487.2012.
81. Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 1881–1882, 2019. doi:10.1056/NEJMoa1812389.
82. Woo AL, Noonan WT, Schultheis PJ, Neumann JC, Manning PA, Lorenz JN, Shull GE. Renal function in NHE3-deficient mice with transgenic rescue of small intestinal absorptive defect. Am J Physiol Renal Physiol 284: F1190 –F1198, 2003. doi:10.1152/ajprenal.00418.2002.
83. Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. Am J Nephrol 49: 331–342, 2019. doi:10.1159/000499597.
84. Yao D, Wang S, Wang M, Lu W. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway. Mol Med Rep 18: 3625–3630, 2018. doi:10. 3892/mmr.2018.9393.
85. CME. Methodist Debakey Cardiovasc J 14: 281–288, 2018. doi:10.14797/mdcj-14-4-281.
86. Yoshikawa T, Kishi T, Shinohara K, Takesue K, Shibata R, Sonoda N, Inoguchi T, Sunagawa K, Tsutsui H, Hirooka Y. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res 40: 646 –651, 2017. doi: 10.1038/hr.2017.14.
87. Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, Nishiyama A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med 65: 1057–1061, 2017. doi:10.1136/jim-2017-000445.
88. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 55: 454–464, 1999. doi:10. 1046/j.1523-1755.1999.00271.x.
89. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015. doi:10.1056/NEJMoa1504720.